Targeting disease pathways in models of Spinal and Bulbar Muscular Atrophy
Targeting disease pathways in models of Spinal and Bulbar Muscular Atrophy
批准号:
2076898
负责人:
金额:
$0.0万
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2018
资助国家:
英国
项目状态:
已结题
起止时间:
2018 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease, is an adult-onset slowly progressing degenerative neuromuscular disorder which predominantly affects males. It is caused by a polyglutamine encoding CAG expansion within the androgen receptor (AR) gene. The AR mediates the effect of androgens such as testosterone and functions as a ligand-dependent transcription factor. However, the molecular basis of muscle atrophy and motor neuron degeneration is as yet unknown. Therefore, the aim of this project is to understand the underlying disease mechanisms in the two primary sites of pathology in SBMA, spinal cord motor neurons and skeletal muscle, allowing for therapeutic targeting of these sites. A well characterised mouse model of SBMA, as well as patient derived stem cell (iPSC) will be used in this study. In particular, analysis will be undertaken on our recent RNA-seq data from laser captured motor neurons from spinal cord and hindlimb muscle of SBMA mice, as well as gene expression data from SBMA patient muscle biopsies to establish the disease pathways. This will be followed up by performing RNA-seq from human stem-cell (h-iPSC) derived motor neurons from SBMA patients. The functional consequences of the genes and pathways dysregulated in SBMA mice, patient iPSCs and patient muscle biopsies will be studied in vitro using primary mouse motor neuron and muscle cultures, as well as patient iPSCs, to establish if targeting these pathways may be a viable therapeutic approach for SBMA. We hope that identification of the genes and pathways that underlie SBMA pathogenesis will lead to in vivo testing of drug targets in a pre-clinical trial in SBMA mice to establish if they have any observable effect on disease progression. Furthermore, by testing potential therapies both in vivo and in vitro, as well in two different models of SBMA, one mouse and the other human derived stem cells, identification of viable therapeutic targets will be greatly enhanced.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
黏液层/细菌被膜双重渗透型抗菌聚多肽纳米载体用于肺部给药治疗慢性阻塞性肺病
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:虞桂平
-
依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
-
批准号:82371255
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹立
-
依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
-
批准号:82372306
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:彭奕冰
-
依托单位:
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
-
批准号:82371251
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:肖勤
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
牙周炎对腹主动脉瘤的作用和机制研究
-
批准号:82370953
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:朱亚琴
-
依托单位:
DJ-1与Calnexin互作调控线粒体—内质网联络区参与帕金森病病理机制的研究
-
批准号:82371414
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄沛
-
依托单位:
DACH1对糖尿病肾病足细胞脂质代谢的调控作用和机制研究
-
批准号:82370719
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹爱丽
-
依托单位: